profit from every $100 of sales.
$0$100
Hologic
We have no price for Hologic since 7 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$76.01+0.00% today
+16.0% since Oct 13, 25
1-year low $65.511-year high $76.01
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $30.00 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Hologic sold, what it kept, and what it did with the cash.
Sales went from $4.86 billion in 2022 to $4.10 billion in 2025, with $566 million of profit last year.
SalesProfit
Hologic handed back 83% of the cash it generated last year.
Buybacks $753M
Free cash flow 2025$905M
Bought back its own shares$753M
Paid as dividends–
Cash vs. debt$2.0B vs. $2.6B
Hologic vs. similar companies
Hologic grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Hologic | 30.0× · Fair price | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Baxter International | No profit yet | ||
 The Cooper Companies | 31.8× · Expensive |
Compare Hologic with GE HealthCare Technologies
AI analysis
An AI analyst reads Hologic's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4,863 | 4,030 | 4,030 | 4,101 | |
| 2,997 | 2,072 | 2,228 | 2,118 | |
| 1,631 | 762 | 931 | 785 | |
| 2,113 | 1,111 | 1,296 | 1,098 | |
| 1,302 | 456 | 790 | 566 | |
| 5.13 | 1.83 | 3.32 | 2.49 | |
| 61.6% | 51.4% | 55.3% | 51.6% | |
| 33.5% | 18.9% | 23.1% | 19.2% | |
| 26.8% | 11.3% | 19.6% | 13.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 9,071 | 9,139 | 9,156 | 9,015 |
| Cash | 2,340 | 2,723 | 2,160 | 1,960 |
| Total debt | 2,922 | 2,904 | 2,658 | 2,627 |
| Total liabilities | 4,195 | 4,122 | 4,026 | 3,967 |
| 4,876 | 5,017 | 5,130 | 5,048 | |
| 254 | 249 | 238 | 228 | |
| 17.1% | 7.9% | 10.0% | 8.2% | |
| 26.7% | 9.1% | 15.4% | 11.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,126 | 1,051 | 1,285 | 1,057 | |
| 127 | 150 | 140 | 152 | |
| 1,999 | 901 | 1,145 | 905 | |
| Dividends paid | – | – | – | – |
| 542 | 475 | 835 | 753 | |
| 67 | 80 | 82 | 84 |
Valuation
- 30.0×
- 17.2×
- –
- 3.3×
- 4.1×
- 18.8×
- 16.1×
- 5.3%
- 3.3%
- 0.0%
Profitability
- 51.6%
- 19.2%
- 13.8%
- 24.6%
- 7.2%
- 13.1%
- 11.0%
- 5.9%
- 8.8%
- 6.0%
Growth
- −5.5%
- −21.4%
- −19.6%
- –
- −3.0%
Financial health
- 0.3×
- 0.48
- 27.5%
- 7.6×
- 4.04
- 3.32
- 0.45
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 41%of 946
Top 25%of 872
Bottom 48%of 563
Bottom 9%of 868
Top 19%of 986
What analysts expect
- Average price target
- $79.00
- Range
- $79.00 – $79.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Jan 29, 2026 | 1.04 | 1.09 | −4.6% |
| Nov 3, 2025 | 1.13 | 1.10 | +2.7% |
| Jul 30, 2025 | 1.08 | 1.05 | +2.9% |
| May 1, 2025 | 1.03 | 1.02 | +1.0% |
| Feb 5, 2025 | 1.03 | 1.02 | +1.0% |
| Nov 4, 2024 | 1.01 | 1.01 | +0.0% |
| Jul 29, 2024 | 1.06 | 1.02 | +3.9% |
| May 2, 2024 | 1.03 | 0.98 | +5.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
52No pass
Philip Fisher
49No pass
Peter Lynch
24No pass
Joel Greenblatt
19No pass
Charlie Munger
59No pass
Terry Smith
54No pass
Questions about Hologic
Is Hologic a good stock to buy?
A solid business at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Hologic AI analysis
What does Hologic do?
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. It is in Medical - Instruments & Supplies, based in Marlborough, MA, United States, with 7,070 employees.
Does Hologic pay a dividend?
No. Hologic does not pay a dividend at the moment; in 2025 it returned $753 million to shareholders by buying back its own shares.
Is Hologic stock halal?
Yes. Hologic passes our halal screen: its business is permitted and its debt is 15% of its market value, under the 30% limit. How we check
Who are Hologic's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Baxter International and The Cooper Companies. The peers table on this page compares their profit, growth and price with Hologic's.
Prices: daily closes to Apr 7, 2026. Fundamentals: company reports via invest-like data.